文献速递头痛与眩晕

慢性头痛与偏头痛患者的支持性自我管理项目:随机对照试验与经济评价

Supportive Self-Management Program for People With Chronic Headaches and Migraine: A Randomized Controlled Trial and Economic Evaluation.
PubMed 文献 · Neurology · 2022-12-16

这项实用的随机对照试验纳入736例慢性偏头痛或慢性紧张型头痛患者,比较2天小组教育加自我管理项目与常规护理加放松材料的效果。12个月时,两组在头痛影响测试(HIT)-6评分和头痛天数上均无显著差异,干预组成本更高但质量调整生命年增益未达统计学显著。

要点

  • 12个月时HIT-6评分组间无显著差异(调整后均数差=-0.3,95%CI -1.23至0.67)。
  • 12个月时每月头痛天数组间无显著差异(调整后均数差=0.9,95%CI -0.29至2.05)。
  • 干预组增量调整成本为268英镑(95%CI 176至377英镑),增量调整QALY为0.031(95%CI -0.005至0.063)。

核心结论

  • 研究结论明确显示,简短期小组教育加支持性自我管理项目对慢性偏头痛或慢性紧张型头痛伴发作性偏头痛患者的生活质量或每月头痛天数无获益。

研究设计与样本

  • 实用随机对照试验,2017年4月至2019年3月随机分配736例18岁及以上慢性偏头痛或慢性紧张型头痛患者,主要从全科诊所招募。
  • 参与者被分配至2天小组教育加自我管理项目、一对一护士访谈和电话支持组,或常规护理加放松材料组。
  • 主要结局为12个月时采用头痛影响测试(HIT)-6评估的头痛相关生活质量,主要分析采用意向性治疗原则,纳入有偏头痛且具有基线和12个月HIT-6数据的参与者。
  • 仅9例参与者仅为紧张型头痛,主要分析基于727例偏头痛参与者,其中376例分配至自我管理干预组,351例分配至常规护理组。
  • 586例(81%)参与者的数据纳入主要结局分析。

主要发现

  • 12个月时HIT-6评分组间无显著差异(调整后均数差=-0.3,95%CI -1.23至0.67)。
  • 12个月时每月头痛天数组间无显著差异(调整后均数差=0.9,95%CI -0.29至2.05)。
  • 慢性头痛教育与自我管理研究干预产生增量调整成本268英镑(95%CI 176至377英镑)(383美元[95%CI 252至539美元])。
  • 增量调整质量调整生命年(QALY)为0.031(95%CI -0.005至0.063),增量成本效果比为每获得1个QALY需8617英镑(12322美元)。

关键数值与推荐

  • 该研究提供III级证据,表明简短期小组教育加自我管理项目不增加慢性偏头痛患者头痛相关生活质量改善的概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仅9例参与者仅为紧张型头痛,主要分析基于727例偏头痛参与者。
  • 586例(81%)参与者的数据纳入主要结局分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Chronic headache disorders are a major cause of pain and disability. Education and supportive self-management approaches could reduce the burden of headache disability. We tested the effectiveness of a group educational and supportive self-management program for people living with chronic headaches. METHODS: This was a pragmatic randomized controlled trial. Participants were aged 18 years or older with chronic migraine or chronic tension-type headache, with or without medication overuse headache. We primarily recruited from general practices. Participants were assigned to either a 2-day group education and self-management program, a one-to-one nurse interview, and telephone support or to usual care plus relaxation material. The primary outcome was headache related-quality of life using the Headache Impact Test (HIT)-6 at 12 months. The primary analysis used intention-to-treat principles for participants with migraine and both baseline and 12-month HIT-6 data. RESULTS: Between April 2017 and March 2019, we randomized 736 participants. Because only 9 participants just had tension-type headache, our main analyses were on the 727 participants with migraine. Of them, 376 were allocated to the self-management intervention and 351 to usual care. Data from 586 (81%) participants were analyzed for primary outcome. There was no between-group difference in HIT-6 (adjusted mean difference = -0.3, 95% CI -1.23 to 0.67) or headache days (0.9, 95% CI -0.29 to 2.05) at 12 months. The Chronic Headache Education and Self-management Study intervention generated incremental adjusted costs of £268 (95% CI, £176-£377) (USD383 [95% CI USD252-USD539]) and incremental adjusted quality-adjusted life years (QALYs) of 0.031 (95% CI -0.005 to 0.063). The incremental cost-effectiveness ratio was £8,617 (USD12,322) per QALY gained. DISCUSSION: These findings conclusively show a lack of benefit for quality of life or monthly headache days from a brief group education and supportive self-management program for people living with chronic migraine or chronic tension-type headache with episodic migraine. TRIAL REGISTRATION INFORMATION: Registered on the International Standard Randomized Controlled Trial Number registry, ISRCTN79708100 16th December 2015 doi.org/10.1186/ISRCTN79708100. The first enrollment was April 24, 2017. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a brief group education and self-management program does not increase the probability of improvement in headache-related quality of life in people with chronic migraine.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Underwood M, Achana F, Carnes D, et al. Supportive Self-Management Program for People With Chronic Headaches and Migraine: A Randomized Controlled Trial and Economic Evaluation. Neurology. 2022. PMID: 36526428. doi:10.1212/WNL.0000000000201518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。